fitusiran
fitusiran: 5 clinical trials tracked.
fitusiran evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about fitusiran, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (5)
An Open-label, Parallel, Phase 3, Two-arm Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B With or Without Inhibitory Antibodies to Factors VIII or IX
Primary endpoint: Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC period
An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fitusiran Prophylaxis in Male Participants Aged ≥12 Years of Age With Severe Hemophilia A, With or Without Inhibitors
Primary endpoint: Number of participants with Adverse events (AEs) during the fitusiran treatment
A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged ≥ 12 Years With Severe Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX
Primary endpoint: Annualized bleeding rate (ABR) in the fitusiran primary efficacy period
ATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
Primary endpoint: Plasma antithrombin (AT) activity levels
An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
Primary endpoint: Number of participants with treatment emergent adverse events (TEAEs)